Interactions between microbiome and lungs: Paving new paths for microbiome based bio-engineered drug delivery systems in chronic respiratory diseases.

摘要: Background The human body is a home to thousands of microbiotas. It defined as community symbiotic, commensal and pathogenic microorganisms that have existed in all exposed sites the body, which co-evolved with diet, lifestyle, genetic factors immune factors. Human microbiotas been studied for years on their effects relation health diseases. Methods Relevant published studies, literature reports were searched from accessible electronic databases related institutional databases. We used keywords, viz; microbiome, microbiota, microbiome drug delivery respiratory disease. Selected articles carefully read through, clustered, segregated into subtopics reviewed. Findings traditional belief sterile lungs was challenged by emergence culture-independent molecular techniques recently introduced invasive broncho-alveolar lavage (BAL) sampling method. constitution lung mainly depends three main ecological factors, include; firstly, immigration microbes airways, secondly, removal airways lastly, regional growth conditions. In healthy conditions, microbial communities co-exist our can build significant pulmonary immunity could act barrier against diseases, whereas, an adverse way, microbiomes may interact other bacteriomes viromes, acting cofactor inflammation host responses, lead progression Thus, use microbiota target, system possible modification disease state, has started gain massive attention recent years. Microbiota, owing its unique characteristics, serve potential system, be bioengineered suit interest. engineered microbiome-derived therapeutics delivered through BC, bacteriophage, bacteria-derived lipid vesicles microbe-derived extracellular vesicles. This review highlights relationships between different types importance towards including role novel systems targeting various